MAP4K1 Inhibitor Compounds for Selective Kinase Modulation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for new compounds that selectively modulate MAP4K1 activity for the treatment of MAP4K1-dependent diseases such as cancer and viral infections, as existing treatments are inadequate in effectively targeting this kinase.
Innovation Solution
The development of specific compounds, represented by various chemical formulas, which act as potent inhibitors of MAP4K1, enhancing immune responses by inhibiting the kinase activity, thereby treating cancer and viral infections.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing treatments are used, then general immune support is provided, but selective targeting of MAP4K1 kinase activity is insufficient
Solution Approach 1:
The patent employs parameter changes by optimizing the chemical structure of inhibitor compounds (Formula I) to achieve selective binding to MAP4K1 kinase. By modifying molecular parameters such as substituent groups (R1-R6), ring structures (Y and B forming 5-7 membered heterocycles), and stereochemistry, the compounds achieve high selectivity for MAP4K1 over other kinases while maintaining potent inhibitory activity with IC50 values in the nanomolar range.
2Reliability
If MAP4K1 kinase activity is attenuated, then anti-tumor immunity may be suppressed, but selective inhibition can enhance anti-tumor immunity
Solution Approach 1:
The patent applies local quality by designing compounds that specifically target the MAP4K1 kinase domain with distinct structural features. The compounds in Formula I exhibit localized interaction with the MAP4K1 active site through specific substituent patterns (R1-R6 groups) and heterocyclic structures, enabling selective inhibition of MAP4K1 without affecting other kinases. This selective local action allows therapeutic inhibition of MAP4K1 in tumor microenvironments while sparing normal immune cell functions that depend on other kinase pathways.
Data Source
AI summary
One embodiment of the disclosure is a compound represented by Formula I or a pharmaceutically acceptable salt thereof. The variables in Formula I are defined herein. Compounds of Formula I are MAP4K1 inhibitors, which can be used to treat a diseases or disorders in a subject that benefits from control of MAP4K1 activity.